Home › Research › Long-term cohort studies
Associations of Mid‐ and Late‐Life Fasting Blood Glucose Levels With Dementia Risk Among Patients With Diabetes: Framingham Heart Study
Jinlei Li, Chunyu Liu, Ting Fang Alvin Ang, Rhoda Au. European Journal of Neurology, 2025-02-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Higher FBG level at midlife was not associated with an increased risk of dementia. For participants with diabetes, higher FBG at age 60 and 70 years was associated with subsequent dementia (HR: 1.72, 95% CI: 1.07-2.75; HR: 1.91, 95% CI: 1.24-2.91). Diabetic participants with first midlife increasing and then late-life declining patterns of FBG were at greater increased risk of dementia compared to participant without diabetes. (HR: 2.00, 95% CI: 1.04-3.85). The relationship between FBG and dementia risk was heterogeneous across the adult age range. Diabetes at midlife is a risk factor for dementia, but high glucose levels at 60-70 years followed by a decline suggests that less controlled diabetes during high age risk for dementia onset may represent another prodromal risk factor and presymptomatic metabolic indicator of dementia.
What this study adds
Evidence grade: Moderate
In this Framingham Heart Study analysis, higher fasting blood glucose at midlife was not linked to increased dementia risk, but among people with diabetes, higher glucose at ages 60 and 70 was linked to later dementia. Reported effect size: HR: 1.72; HR: 1.91; HR: 2.00.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Li, J., Liu, C., Ang, T. F. A., & Au, R. (2025). Associations of Mid‐ and Late‐Life Fasting Blood Glucose Levels With Dementia Risk Among Patients With Diabetes: Framingham Heart Study. European Journal of Neurology. https://doi.org/10.1111/ene.70062
Vancouver
Li J, Liu C, Ang TFA, Au R. Associations of Mid‐ and Late‐Life Fasting Blood Glucose Levels With Dementia Risk Among Patients With Diabetes: Framingham Heart Study. European Journal of Neurology. 2025. doi:10.1111/ene.70062. PMID: 39910859.
BibTeX
@article{li2025-39910859,
author = {Li, Jinlei and Liu, Chunyu and Ang, Ting Fang Alvin and Au, Rhoda},
title = {{Associations of Mid‐ and Late‐Life Fasting Blood Glucose Levels With Dementia Risk Among Patients With Diabetes: Framingham Heart Study}},
journal = {European Journal of Neurology},
year = {2025},
doi = {10.1111/ene.70062},
pmid = {39910859},
url = {https://doi.org/10.1111/ene.70062}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Higher FBG level at midlife was not associated with an increased risk of dementia.
- For participants with diabetes, higher FBG at age 60 and 70 years was associated with subsequent dementia (HR: 1.72, 95% CI: 1.07-2.75; HR: 1.91, 95% CI: 1.24-2.91).
- Diabetic participants with first midlife increasing and then late-life declining patterns of FBG were at greater increased risk of dementia compared to participant without diabetes.
- The relationship between FBG and dementia risk was heterogeneous across the adult age range.
- Diabetes at midlife is a risk factor for dementia, but high glucose levels at 60-70 years followed by a decline suggests that less controlled diabetes during high age risk for dementia onset may represent another prodromal risk factor and presymptomatic metabolic indicator of dementia.
Why it matters
In this Framingham Heart Study analysis, higher fasting blood glucose at midlife was not linked to increased dementia risk, but among people with diabetes, higher glucose at ages 60 and 70 was linked to later dementia. The authors suggest poorly controlled diabetes at older ages may be a presymptomatic metabolic indicator of dementia, but no treatment is tested.
Study details
- Effect sizeHR: 1.72; HR: 1.91; HR: 2.00
- Evidence strengthModerate
How this study scored 44/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (European Journal of Neurology) |
| Journal's citation record | 2 / 4 | European Journal of Neurology: journal h-index 181 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 4 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 2.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 1 / 4 | Cited 4 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Rhoda Au: h-index 90 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Boston University: institution h-index 1,456 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39910859) |
| Free to read | 2 / 2 | Free to read |
| Total | 44 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1111/ene.70062
- PubMed: 39910859
- Original source →
- Free full text: European Journal of Neurology →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 17.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Long-term cohort studies from nearby years
Also tagged “biobank”
1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.